A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma
1977; Wiley; Volume: 40; Issue: 5 Linguagem: Inglês
10.1002/1097-0142(197711)40
ISSN1097-0142
AutoresJ. Frederick Laucius, A. Bodurtha, Michael J. Mastrangelo, Robert E. Bellet,
Tópico(s)Immunotherapy and Immune Responses
ResumoEighteen patients with surgically incurable metastatic malignant melanoma were treated with a mixture of irradiated (15,000 rads) autologous tumor cells (1-2 × 108) and BCG (Glaxo, 2-4.5 × 106 organisms), which was injected intradermally (in five divided doses) every 2 weeks (X5). Four of 18 (22%) evaluable patients achieved objective remissions. It is concluded that this treatment regimen does not have general clinical application because the remissions were infrequent, of short duration (median, 3 months) and occurred only in patients with minimal, nonvisceral tumor burdens.
Referência(s)